CXCL9 and neoplasm: However, it has been well documented that CXCL9, 10, and 11 play crucial roles in immune activation and tumor rejection in TME via its cognate receptor, CXCR312, and anti-tumor effect of anti-PD-1 therapy decreases in CXCR3 knock-out mice13.